PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations.

导出 OA

翻译打印收藏纠错

第一作者： Helen Y,Zou

第一单位： Oncology Research Unit, helen.zou@pfizer.com.

作者： Helen Y,Zou ^[1] ; Qiuhua,Li ^[2] ; Lars D,Engstrom ^[2] ; Melissa,West ^[2] ; Vicky,Appleman ^[3] ; Katy A,Wong ^[3] ; Michele,McTigue ^[4] ; Ya-Li,Deng ^[4] ; Wei,Liu ^[4] ; Alexei,Brooun ^[4] ; Sergei,Timofeevski ^[2] ; Scott R P,McDonnell ^[2] ; Ping,Jiang ^[2] ; Matthew D,Falk ^[2] ; Patrick B,Lappin ^[5] ; Timothy,Affolter ^[5] ; Tim,Nichols ^[5] ; Wenyue,Hu ^[5] ; Justine,Lam ^[6] ; Ted W,Johnson ^[4] ; Tod,Smeal ^[2] ; Al,Charest ^[7] ; Valeria R,Fantin ^[2]

作者单位： Oncology Research Unit, helen.zou@pfizer.com. ^[1] Oncology Research Unit. ^[2] Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111; and. ^[3] Oncology Medicinal Chemistry. ^[4] Drug Safety Research and Development, and. ^[5] Pharmacokinetics-Dynamics-Metabolism, Pfizer Worldwide Research, La Jolla, CA 92121; ^[6] Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA 02111; and Department of Neurosurgery, Tufts University School of Medicine, Boston, MA 02111. ^[7]

关键词 PF-06463922 ROS1 kinase inhibitor